[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"nav-categories":3,"article-longevity-investment-market-soars-to-8-49-billion-in-2024-a-steady-climb-fueled-by-big-pharma":70},{"data":4},[5,37,57,64],{"name":6,"slug":7,"categories":8},"Productivity","productivity",[9,13,17,21,25,29,33],{"id":10,"title":11,"slug":12},17,"Branding","branding",{"id":14,"title":15,"slug":16},19,"Marketing","marketing",{"id":18,"title":19,"slug":20},20,"Work","work",{"id":22,"title":23,"slug":24},34,"Community","community",{"id":26,"title":27,"slug":28},21,"For newbies","for-newbies",{"id":30,"title":31,"slug":32},24,"Investment","investment",{"id":34,"title":35,"slug":36},22,"Finance","finance",{"name":38,"slug":39,"categories":40},"Tech","tech",[41,45,49,53],{"id":42,"title":43,"slug":44},28,"Technology","technology",{"id":46,"title":47,"slug":48},32,"Artificial Intelligence","artificial-intelligence",{"id":50,"title":51,"slug":52},26,"Security and protection","security-and-protection",{"id":54,"title":55,"slug":56},31,"YouTube Blog","youtube-blog",{"name":58,"slug":59,"categories":60},"News","news",[61],{"id":62,"title":58,"slug":63},18,"quasanews",{"name":65,"slug":66,"categories":67},"Business","business",[68],{"id":69,"title":65,"slug":66},16,{"post":71,"published_news":97,"popular_news":163,"categories":234},{"title":72,"description":73,"meta_title":72,"meta_description":74,"meta_keywords":75,"text":76,"slug":77,"created_at":78,"publish_at":79,"formatted_created_at":80,"category_id":30,"links":81,"view_type":86,"video_url":87,"views":88,"likes":89,"lang":90,"comments_count":89,"category":91},"Longevity Investment Market Soars to $8.49 Billion in 2024: A Steady Climb Fueled by Big Pharma","The longevity investment market is thriving, signaling a maturing industry that’s moving beyond fleeting hype to sustained growth. In 2024, the sector saw an impressive $8.49 billion in investments across 325 deals, more than doubling the $3.82 billion recorded in 2023, according to the 2024 Annual Longevity Investment Report by Longevity.Technology. While not yet reaching the feverish peak of 2021, this rebound reflects growing confidence and a strategic shift toward later-stage clinical development and platform technologies. With major pharmaceutical companies entering the fray, hunting for late-stage trial projects and striking massive licensing deals—some worth up to half a billion dollars—the longevity sector is proving it’s no longer a speculative gamble but a cornerstone of future healthcare.","The United States remains the epicenter of longevity innovation, hosting 57% of longevity companies and securing 84% of total deal volume.","The longevity investment market is thriving, signaling a maturing industry that’s moving beyond fleeting hype to sustained growth.","\u003Cp>The longevity investment market is thriving, signaling a maturing industry that’s moving beyond fleeting hype to sustained growth. In 2024, the sector saw an impressive \u003Cstrong>$8.49 billion\u003C/strong> in investments across 325 deals, more than doubling the $3.82 billion recorded in 2023, according to the 2024 Annual Longevity Investment Report by Longevity.Technology.\u003C/p>\n\n\u003Cp>While not yet reaching the feverish peak of 2021, this rebound reflects growing confidence and a strategic shift toward later-stage clinical development and platform technologies. With major pharmaceutical companies entering the fray, hunting for late-stage trial projects and striking massive licensing deals—some worth up to half a billion dollars — the longevity sector is proving it’s no longer a speculative gamble but a cornerstone of future healthcare.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>A Resurgent Market with Focused Momentum\u003C/strong>\u003C/h4>\n\n\u003Cp>\u003Cpicture class=\"image-align-left\">\u003Csource srcset=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102020892.webp\" type=\"image/webp\">\u003Cimg alt=\"Longevity Investment Market Soars to .49 Billion in 2024: A Steady Climb Fueled by Big Pharma\" class=\"image-align-left\" height=\"333\" src=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102020892.jpg\" width=\"250\" />\u003C/picture>After a cautious 2023 marked by economic contraction, 2024 was a year of renewed vigor for longevity biotech. The year kicked off with a robust \u003Cstrong>$3.74 billion raised in Q1\u003C/strong>, setting a strong trajectory that culminated in $1.75 billion in Q4. Unlike the early-stage exuberance of 2021, this year’s investments leaned heavily toward \u003Cstrong>later-stage venture capital (VC)\u003C/strong>, which accounted for \u003Cstrong>31% of total funding\u003C/strong>.\u003C/p>\n\n\u003Cp>This shift underscores a market prioritizing execution over experimentation, with investors betting on companies poised to deliver tangible results.\u003C/p>\n\n\u003Cp>The United States remains the epicenter of longevity innovation, hosting \u003Cstrong>57% of longevity companies\u003C/strong> and securing \u003Cstrong>84% of total deal volume\u003C/strong>. Longevity discovery platforms, which enhance biomarker development and therapeutic screening, emerged as the top-funded domain, attracting \u003Cstrong>$2.65 billion\u003C/strong>.\u003C/p>\n\n\u003Cp>Notable highlights include \u003Cstrong>BioAge Labs’ $200 million IPO\u003C/strong>, focused on metabolic diseases, and \u003Cstrong>Jupiter Neurosciences’ public listing\u003C/strong>, targeting neuroinflammation with resveratrol-based therapies.\u003C/p>\n\n\u003Cp>These milestones, alongside major funding rounds for senotherapeutics startup \u003Cstrong>Rubedo Life Sciences\u003C/strong> and dog longevity biotech \u003Cstrong>Loyal\u003C/strong>, highlight the sector’s growing maturity.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>Big Pharma’s Big Bet on Longevity\u003C/strong>\u003C/h4>\n\n\u003Cp>\u003Cpicture class=\"image-align-right\">\u003Csource srcset=\"https://cdn.quasa.io/photos/01/image-2025-07-03t101924880.webp\" type=\"image/webp\">\u003Cimg alt=\"Longevity Investment Market Soars to .49 Billion in 2024: A Steady Climb Fueled by Big Pharma\" class=\"image-align-right\" height=\"333\" src=\"https://cdn.quasa.io/photos/01/image-2025-07-03t101924880.jpg\" width=\"250\" />\u003C/picture>A key driver of 2024’s growth is the increasing involvement of large pharmaceutical companies, which are now actively seeking late-stage projects to bolster their pipelines. Facing looming patent cliffs for blockbuster drugs, giants like \u003Cstrong>Eli Lilly, AstraZeneca, and Novartis\u003C/strong> are diving into longevity through strategic licensing deals and acquisitions.\u003C/p>\n\n\u003Cp>For instance, \u003Cstrong>BioAge Labs’ collaboration with Eli Lilly\u003C/strong> on its muscle-preserving compound azelaprag, combined with Lilly’s Zepbound, showcased the potential for longevity-focused therapeutics, despite a later trial halt due to safety concerns. Meanwhile, \u003Cstrong>Fauna Bio’s $494 million deal with Eli Lilly\u003C/strong> in 2023 set a precedent for megadeals, with similar half-billion-dollar licensing agreements becoming more common in 2024.\u003C/p>\n\n\u003Cp>These partnerships reflect Big Pharma’s recognition that longevity therapies — targeting aging mechanisms like cellular senescence, mitochondrial dysfunction, and epigenetic reprogramming — could redefine healthcare. The high cost of longevity drug development, often exceeding \u003Cstrong>$6.1 billion\u003C/strong> with failure rates above \u003Cstrong>90%\u003C/strong>, necessitates the deep pockets and infrastructure of major players.\u003C/p>\n\n\u003Cp>Their expertise in navigating complex, multi-site clinical trials and regulatory hurdles is critical for advancing promising candidates, such as senolytics or metformin, which is under investigation for its anti-aging potential.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>A Shift Toward Stability and Scale\u003C/strong>\u003C/h4>\n\n\u003Cp>\u003Cpicture class=\"image-align-left\">\u003Csource srcset=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102019632.webp\" type=\"image/webp\">\u003Cimg alt=\"Longevity Investment Market Soars to .49 Billion in 2024: A Steady Climb Fueled by Big Pharma\" class=\"image-align-left\" height=\"267\" src=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102019632.jpg\" width=\"200\" />\u003C/picture>Unlike the hype-driven surges of previous years, 2024’s growth is characterized by a \u003Cstrong>selective, mature market approach\u003C/strong>. Investors are prioritizing \u003Cstrong>platform technologies\u003C/strong> that streamline drug discovery and improve trial efficiency, signaling a belief that the future of longevity lies in robust infrastructure.\u003C/p>\n\n\u003Cp>Companies like Insilico Medicine, leveraging AI to accelerate drug discovery for age-related diseases, and \u003Cstrong>Altos Labs\u003C/strong>, backed by Jeff Bezos and focused on cellular rejuvenation, are leading the charge. Insilico’s AI-driven drug for idiopathic pulmonary fibrosis, now in Phase 2 trials, and Altos’ human trials for neurodegenerative disorders exemplify the sector’s push toward clinical validation.\u003C/p>\n\n\u003Cp>The market’s evolution is also evident in its non-pharmaceutical advancements. Consumer-focused longevity companies, such as \u003Cstrong>ŌURA\u003C/strong> (raising $200 million for its smart ring) and \u003Cstrong>Function Health\u003C/strong> ($53 million for personalized diagnostics), are gaining traction, reflecting growing public interest in healthspan extension.\u003C/p>\n\n\u003Cp>These developments, combined with the proliferation of longevity clinics worldwide, indicate a broadening ecosystem that spans therapeutics, diagnostics, and consumer wellness.\u003C/p>\n\n\u003Chr />\n\u003Ch4>\u003Cstrong>Challenges and Opportunities\u003C/strong> Ahead\u003C/h4>\n\n\u003Cp>Despite the optimism, challenges loom. The \u003Cstrong>high cost and risk of clinical trials \u003C/strong>— with median costs of \u003Cstrong>$48 million per drug\u003C/strong> and per-patient expenses around \u003Cstrong>$41,413 \u003C/strong>— pose significant barriers, particularly for smaller biotechs. Regulatory uncertainty around longevity therapies, especially whether aging will be classified as a treatable condition, remains a hurdle. Additionally, the sector must address ethical concerns and ensure equitable access, as-advanced therapies risk being limited to high-income markets.\u003C/p>\n\n\u003Cp>Looking to 2025, analysts project the longevity market to grow to \u003Cstrong>$9.8 billion\u003C/strong>, a 1\u003Cstrong>15% year-over-year increase\u003C/strong>, driven by institutional capital, renewed IPO interest, and sustained VC appetite. Emerging trends to watch include \u003Cstrong>cross-over trials combining senotherapeutics with mitochondrial therapies\u003C/strong>, novel delivery methods like nanoparticle formulations, and dual-modality platforms targeting multiple aging hallmarks\u003C/p>\n\n\u003Chr />\n\u003Cp>\u003Cstrong>\u003Cpicture class=\"image-align-right\">\u003Csource srcset=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102246230.webp\" type=\"image/webp\">\u003Cimg alt=\"Longevity Investment Market Soars to .49 Billion in 2024: A Steady Climb Fueled by Big Pharma\" class=\"image-align-right\" height=\"400\" src=\"https://cdn.quasa.io/photos/01/image-2025-07-03t102246230.jpg\" width=\"300\" />\u003C/picture>Also read:\u003C/strong>\u003C/p>\n\n\u003Cul>\n\t\u003Cli>\u003Ca href=\"https://quasa.io/media/spotify-s-bold-video-push-leaked-deck-reveals-ambitious-creator-strategy\">Spotify’s Bold Video Push: Leaked Deck Reveals Ambitious Creator Strategy\u003C/a>\u003C/li>\n\t\u003Cli>\u003Ca href=\"https://quasa.io/media/sam-altman-fires-back-at-meta-after-zuckerberg-poaches-openai-talent\">Sam Altman Fires Back at Meta After Zuckerberg Poaches OpenAI Talent\u003C/a>\u003C/li>\n\t\u003Cli>\u003Ca href=\"https://quasa.io/media/u-s-senate-overwhelmingly-rejects-ai-regulation-ban-in-big-beautiful-bill\">U.S. Senate Overwhelmingly Rejects AI Regulation Ban in Big Beautiful Bill\u003C/a>\u003C/li>\n\u003C/ul>\n\n\u003Ch4>\u003Cstrong>The Future of Longevity\u003C/strong>\u003C/h4>\n\n\u003Cp>InvestmentThe longevity investment market’s $8.49 billion haul in 2024 marks a pivotal moment—a shift from speculative enthusiasm to a disciplined, results-driven industry. With Big Pharma’s growing involvement, late-stage clinical progress, and a focus on scalable platform technologies, the sector is laying the foundation for transformative healthcare advancements.\u003C/p>\n\n\u003Cp>While challenges like high costs and regulatory hurdles persist, the trajectory is clear: longevity is no longer a fringe pursuit but a mainstream investment opportunity with the potential to reshape how we age. For investors, researchers, and consumers, 2024’s surge is a call to action — get involved now, because the future of healthy aging is taking shape today\u003C/p>\n\n\u003Cp>Author: \u003Ca href=\"https://www.linkedin.com/in/slava-vasipenok/\">Slava Vasipenok\u003C/a>\u003Cbr />\nFounder and CEO of \u003Ca href=\"https://quasa.io/team\">QUASA\u003C/a> (quasa.io) - Daily insights on Web3, AI, Crypto, and Freelance. Stay updated on finance, technology trends, and creator tools - with sources and real value.\u003C/p>\n\n\u003Cp>Innovative entrepreneur with over 20 years of experience in IT, fintech, and blockchain. Specializes in decentralized solutions for freelancing, helping to overcome the barriers of traditional finance, especially in developing regions.\u003C/p>\n\n\u003Cp>This is not financial or investment advice. Always do your own research (DYOR).\u003C/p>","longevity-investment-market-soars-to-8-49-billion-in-2024-a-steady-climb-fueled-by-big-pharma","2025-07-03T08:22:00.000000Z","2025-07-19T01:18:00.000000Z","19.07.2025",{"image":82,"image_webp":83,"thumb":84,"thumb_webp":85},"https://cdn.quasa.io/images/news/9EbzopQ3Ze8SW7rAP9Jne0JER511qE8p7AFLZeWe.jpg","https://cdn.quasa.io/images/news/9EbzopQ3Ze8SW7rAP9Jne0JER511qE8p7AFLZeWe.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/9EbzopQ3Ze8SW7rAP9Jne0JER511qE8p7AFLZeWe.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/9EbzopQ3Ze8SW7rAP9Jne0JER511qE8p7AFLZeWe.webp","small",null,3342,0,"en",{"id":30,"title":31,"slug":32,"meta_title":92,"meta_description":93,"meta_keywords":94,"deleted_at":87,"created_at":95,"updated_at":96,"lang":90},"Quasa Media Blog about Growth Hacking in Investing","Investments and life hacks. Forecasts and investment trends in Quasa Media.","Investment, IPO, bonds, Gold, invest. Investments, investor","2021-12-10T10:41:35.000000Z","2024-08-25T15:37:37.000000Z",[98,113,126,138,150],{"title":99,"description":100,"slug":101,"created_at":102,"publish_at":103,"formatted_created_at":104,"category":105,"links":106,"view_type":86,"video_url":87,"views":111,"likes":89,"lang":90,"comments_count":89,"is_pinned":112},"Baidu Drops ERNIE-Image: A Compact 8B Open-Source Text-to-Image Model That Tops the Charts","Baidu has just released ERNIE-Image — a new open-weight text-to-image generator that is already turning heads in the AI community.","baidu-drops-ernie-image-a-compact-8b-open-source-text-to-image-model-that-tops-the-charts","2026-04-17T11:57:35.000000Z","2026-04-20T03:44:00.000000Z","20.04.2026",{"title":47,"slug":48},{"image":107,"image_webp":108,"thumb":109,"thumb_webp":110},"https://cdn.quasa.io/images/news/1QiOJcmqi34aQvnRfCwi97GmGUD4JPEukbjf4csU.jpg","https://cdn.quasa.io/images/news/1QiOJcmqi34aQvnRfCwi97GmGUD4JPEukbjf4csU.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/1QiOJcmqi34aQvnRfCwi97GmGUD4JPEukbjf4csU.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/1QiOJcmqi34aQvnRfCwi97GmGUD4JPEukbjf4csU.webp",13,false,{"title":114,"description":115,"slug":116,"created_at":117,"publish_at":117,"formatted_created_at":118,"category":119,"links":120,"view_type":86,"video_url":87,"views":125,"likes":89,"lang":90,"comments_count":89,"is_pinned":112},"Cloudflare Just Made Email a First-Class Citizen for AI Agents — And Traditional Email Services Are Feeling It","On April 17, 2026, Cloudflare quietly turned a long-standing dream into reality: it moved Email Service into public beta and added full Email Sending alongside the years-old Email Routing.","cloudflare-just-made-email-a-first-class-citizen-for-ai-agents-and-traditional-email-services-are-feeling-it","2026-04-19T18:41:05.000000Z","19.04.2026",{"title":43,"slug":44},{"image":121,"image_webp":122,"thumb":123,"thumb_webp":124},"https://cdn.quasa.io/images/news/BL8rqDdPh380Xfk5TP00aXBFWdOVXI5BUQ1TuSaC.jpg","https://cdn.quasa.io/images/news/BL8rqDdPh380Xfk5TP00aXBFWdOVXI5BUQ1TuSaC.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/BL8rqDdPh380Xfk5TP00aXBFWdOVXI5BUQ1TuSaC.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/BL8rqDdPh380Xfk5TP00aXBFWdOVXI5BUQ1TuSaC.webp",62,{"title":127,"description":128,"slug":129,"created_at":130,"publish_at":130,"formatted_created_at":118,"category":131,"links":132,"view_type":86,"video_url":87,"views":137,"likes":89,"lang":90,"comments_count":89,"is_pinned":112},"Mozilla Nails It: Thunderbolt Brings “ChatGPT at Home” to the Enterprise — Without Vendor Lock-In","While OpenAI and Anthropic race to sell their proprietary AI platforms to big corporations, Mozilla’s subsidiary MZLA Technologies has taken a very different route.","mozilla-nails-it-thunderbolt-brings-chatgpt-at-home-to-the-enterprise-without-vendor-lock-in","2026-04-19T15:37:27.000000Z",{"title":58,"slug":63},{"image":133,"image_webp":134,"thumb":135,"thumb_webp":136},"https://cdn.quasa.io/images/news/qaAODXSpJy6qpJc0eO9DQ2Y6ccJR1tlL5i3mN0kV.jpg","https://cdn.quasa.io/images/news/qaAODXSpJy6qpJc0eO9DQ2Y6ccJR1tlL5i3mN0kV.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/qaAODXSpJy6qpJc0eO9DQ2Y6ccJR1tlL5i3mN0kV.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/qaAODXSpJy6qpJc0eO9DQ2Y6ccJR1tlL5i3mN0kV.webp",78,{"title":139,"description":140,"slug":141,"created_at":142,"publish_at":142,"formatted_created_at":118,"category":143,"links":144,"view_type":86,"video_url":87,"views":149,"likes":89,"lang":90,"comments_count":89,"is_pinned":112},"X Is Finally Cracking Down on Unlabeled Ads — And It’s Personal","For years, X (formerly Twitter) has been a playground for undisclosed promotions, coordinated spam networks, and “native” advertising that masquerades as organic content.","x-is-finally-cracking-down-on-unlabeled-ads-and-it-s-personal","2026-04-19T15:07:48.000000Z",{"title":65,"slug":66},{"image":145,"image_webp":146,"thumb":147,"thumb_webp":148},"https://cdn.quasa.io/images/news/CQJ1gdssFGyJpfhfmRU2X4WT5fk5Boc8APXsjWX6.jpg","https://cdn.quasa.io/images/news/CQJ1gdssFGyJpfhfmRU2X4WT5fk5Boc8APXsjWX6.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/CQJ1gdssFGyJpfhfmRU2X4WT5fk5Boc8APXsjWX6.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/CQJ1gdssFGyJpfhfmRU2X4WT5fk5Boc8APXsjWX6.webp",80,{"title":151,"description":152,"slug":153,"created_at":154,"publish_at":155,"formatted_created_at":118,"category":156,"links":157,"view_type":86,"video_url":87,"views":162,"likes":89,"lang":90,"comments_count":89,"is_pinned":112},"Bitcoin Developers Propose BIP-361: Quantum-Proof Migration That Would Freeze Millions of Legacy Coins","In a move that could reshape the security of Bitcoin’s unspent transaction outputs forever, Bitcoin developers have introduced BIP-361 — officially titled “Post Quantum Migration and Legacy Signature Sunset.”","bitcoin-developers-propose-bip-361-quantum-proof-migration-that-would-freeze-millions-of-legacy-coins","2026-04-17T11:38:06.000000Z","2026-04-19T11:29:00.000000Z",{"title":43,"slug":44},{"image":158,"image_webp":159,"thumb":160,"thumb_webp":161},"https://cdn.quasa.io/images/news/XW07GuAbFLRaVskP2iUsv0witLmM4GwiSlwMPZpp.jpg","https://cdn.quasa.io/images/news/XW07GuAbFLRaVskP2iUsv0witLmM4GwiSlwMPZpp.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/XW07GuAbFLRaVskP2iUsv0witLmM4GwiSlwMPZpp.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/XW07GuAbFLRaVskP2iUsv0witLmM4GwiSlwMPZpp.webp",99,[164,177,193,205,220],{"title":165,"description":166,"slug":167,"created_at":168,"publish_at":169,"formatted_created_at":170,"category":171,"links":172,"view_type":86,"video_url":87,"views":175,"likes":176,"lang":90,"comments_count":89,"is_pinned":112},"The Anatomy of an Entrepreneur","Entrepreneur is a French word that means an enterpriser. Enterprisers are people who undertake a business or enterprise with the chance of earning profits or suffering from loss.","the-anatomy-of-an-entrepreneur","2021-08-04T15:18:21.000000Z","2025-12-14T06:09:00.000000Z","14.12.2025",{"title":65,"slug":66},{"image":173,"image_webp":87,"thumb":174,"thumb_webp":174},"https://cdn.quasa.io/images/news/mVsXPTMuHZuI7UXCsENgL1Qwp1uSOf7Rz3uVPMfm.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/mVsXPTMuHZuI7UXCsENgL1Qwp1uSOf7Rz3uVPMfm.webp",70876,2,{"title":178,"description":179,"slug":180,"created_at":181,"publish_at":182,"formatted_created_at":183,"category":184,"links":185,"view_type":190,"video_url":87,"views":191,"likes":192,"lang":90,"comments_count":89,"is_pinned":112},"Advertising on QUASA","QUASA MEDIA is read by more than 400 thousand people a month. We offer to place your article, add a link or order the writing of an article for publication.","advertising-on-quasa","2022-07-06T07:33:02.000000Z","2025-12-15T17:33:02.000000Z","15.12.2025",{"title":58,"slug":63},{"image":186,"image_webp":187,"thumb":188,"thumb_webp":189},"https://cdn.quasa.io/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.jpg","https://cdn.quasa.io/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/45SvmdsTQbiyc3nxgbyHY1mpVbisYyub2BCHjqBL.webp","large",70641,4,{"title":194,"description":195,"slug":196,"created_at":197,"publish_at":198,"formatted_created_at":199,"category":200,"links":201,"view_type":86,"video_url":87,"views":204,"likes":192,"lang":90,"comments_count":89,"is_pinned":112},"What is a Startup?","A startup is not a new company, not a tech company, nor a new tech company. You can be a new tech company, if your goal is not to grow high and fast; then, you are not a startup. ","what-is-a-startup","2021-08-04T12:05:17.000000Z","2025-12-17T13:02:00.000000Z","17.12.2025",{"title":65,"slug":66},{"image":202,"image_webp":87,"thumb":203,"thumb_webp":203},"https://cdn.quasa.io/images/news/EOsQhSW3VXyG7a6NPdE1oZd00xfJXe3bjY5aJGb7.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/EOsQhSW3VXyG7a6NPdE1oZd00xfJXe3bjY5aJGb7.webp",68272,{"title":206,"description":207,"slug":208,"created_at":209,"publish_at":210,"formatted_created_at":211,"category":212,"links":213,"view_type":86,"video_url":87,"views":218,"likes":176,"lang":90,"comments_count":219,"is_pinned":112},"Top 5 Tips to Make More Money as a Content Creator","Content creators are one of the most desired job titles right now. Who wouldn’t want to earn a living online?","top-5-tips-to-make-more-money-as-a-content-creator","2022-01-17T17:31:51.000000Z","2026-01-17T11:30:00.000000Z","17.01.2026",{"title":19,"slug":20},{"image":214,"image_webp":215,"thumb":216,"thumb_webp":217},"https://cdn.quasa.io/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.jpg","https://cdn.quasa.io/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/gP8kiumBPpJmQv6SMieXiX1tDetx43VwFfO1P4Ca.webp",42243,1,{"title":221,"description":222,"slug":223,"created_at":224,"publish_at":225,"formatted_created_at":226,"category":227,"links":228,"view_type":190,"video_url":87,"views":233,"likes":176,"lang":90,"comments_count":89,"is_pinned":112},"8 Logo Design Tips for Small Businesses","Your logo tells the story of your business and the values you stand for.","8-logo-design-tips-for-small-businesses","2021-12-04T21:59:52.000000Z","2025-05-05T03:30:00.000000Z","05.05.2025",{"title":15,"slug":16},{"image":229,"image_webp":230,"thumb":231,"thumb_webp":232},"https://cdn.quasa.io/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.jpg","https://cdn.quasa.io/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.webp","https://cdn.quasa.io/thumbs/news-thumb/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.jpg","https://cdn.quasa.io/thumbs/news-thumb/images/news/Wbx2NtS1CnTupgoQbpFMGspJ5jm4uob2hDOq33r0.webp",41337,[235,236,237,238,239,240,241,242,243,244,245,246,247],{"title":23,"slug":24},{"title":47,"slug":48},{"title":55,"slug":56},{"title":43,"slug":44},{"title":51,"slug":52},{"title":31,"slug":32},{"title":35,"slug":36},{"title":27,"slug":28},{"title":19,"slug":20},{"title":15,"slug":16},{"title":58,"slug":63},{"title":11,"slug":12},{"title":65,"slug":66}]